Yes, ADC Therapeutics operates as a specialized commercial-stage biotechnology and pharmaceutical enterprise focusing on the discovery, development, and commercialization of proprietary oncology drugs. Its core scientific expertise lies in specialized antibody-drug conjugates (ADCs) designed to target and destroy hematological malignancies and solid tumor cancers while minimizing systemic toxicity to healthy tissues, positioning it firmly within the advanced pharmaceutical sector.